Breaking Finance News

H.C. Wainwright announced Fate Therapeutics (NDAQ:FATE), bumping up its stock price target to $7.00 today

In a report released on 10/12/2017 H.C. Wainwright increased the stock price target of Fate Therapeutics (NDAQ:FATE) to $7.00 reporting a possible upside of 0.76%.

Previously on 9/8/2017, Leerink Swann reported on Fate Therapeutics (NDAQ:FATE) increased the target price from $0.00 to $7.00. At the time, this indicated a possible upside of 0.70%.

Just yesterday Fate Therapeutics (NDAQ:FATE) traded -1.95% lower at $3.98. Fate Therapeutics’s 50-day moving average is $3.97 and its 200-day moving average is $3.68. The last closing price is up 9.41% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 241,638 shares of FATE traded hands, up from an average trading volume of 233,025

Recent Performance Chart

Fate Therapeutics (NDAQ:FATE)

Fate Therapeutics has 52 week low of $1.80 and a 52 week high of $5.68 and has a market capitalization of $0.

In addition to H.C. Wainwright reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $6.25 with 3 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Fate Therapeutics (NDAQ:FATE)

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.